U.S. Dry Eye Disease Diagnostic Devices Market

U.S. Dry Eye Disease Diagnostic Devices Market (Device Type: Anterior Segment OCT, Meibography Device, Corneal Topographer, Interferometer, Fluorophotometer, and Others; Disease and End-user) - Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

U.S. Dry Eye Disease Diagnostic Devices Market Outlook 2031

  • The U.S. dry eye disease diagnostic devices market was valued at US$ 58.3 Mn in 2020
  • It is estimated to expand at a CAGR of 4.4% from 2021 to 2031
  • The U.S. dry eye disease diagnostic devices market is expected to reach the value of US$ 99.4 Mn by the end of 2031

Analysts’ Viewpoint on U.S. Dry Eye Disease Diagnostic Devices Market Scenario

Environmental factors such as air quality and personal behaviors including prolonged use of digital devices, which include mobile phones and VDTs are increasing the risk of DED during the ongoing coronavirus pandemic. Due to lack of accuracy in diagnosing DED, med-tech companies are increasing R&D in devices that use deep learning-based artificial intelligence algorithms to standardize clinical dry eye tests. On the other hand, AS-OCT is being publicized for including fast, non-contact, and in-vivo imaging of corneal structures. Med-tech companies are increasing the availability of meibography devices, since early diagnosis of MGD helps to prevent corneal damage and vision loss.

Meibography Devices Ensure Thorough Eye Examination with HD Definition Imaging Technology

Meibography is revolutionizing the U.S. dry eye disease diagnostic devices market. The high prevalence of meibomian gland dysfunction (MGD) among individuals is translating into value-grab opportunities for market stakeholders. As such, meibography is gaining popularity as a non-invasive screening tool for MGD and enables ophthalmologists to provide effective treatment to relieve dry eye symptoms.

Companies in the U.S. dry eye disease diagnostic devices market are increasing the availability of meibography devices to ensure a thorough clinical examination of the eyes with the help of high definition (HD) imaging technology. Eye doctors are using meibography devices to view the health of meibomian glands with optimum accuracy.

Prolonged Exposure to VDTs Increases Risk of DED amid Coronavirus Pandemic

The prolonged use of video display terminals (VDTs) has increased the risk of ocular surface disorders such as the dry eye disease (DED) amid the ongoing coronavirus pandemic. Stakeholders in the U.S. dry eye disease diagnostic devices market are gaining cognizance about these findings and increasing the availability of tools.

Even as DED is among the most common eye diseases in the U.S., the pandemic poses risks for DED patients. Nevertheless, participants in the U.S. dry eye disease diagnostic devices market are increasingly focusing on telehealth services and eHealth to stay future-ready in the healthcare landscape. Healthcare providers and med-tech companies are reinventing their care services and product distribution, respectively. The abusive use of mobile phones and TVs, owing to work-from-home settings may lead to poor quality of blinking, thus increasing the risk of DED.

Tests and Devices with Deep Learning Models Hold Potentials to Improve Patient Outcomes

Accurately diagnosing and managing DED is potentially challenging. It has been found that there is a lack of gold standard test for DED diagnosis. Hence, apart from increasing research in anterior segment optical coherence tomography (AS-OCT), med-tech companies are innovating in devices with high sensitivity, specificity, and accuracy for autonomously distinguishing DED from healthy patients.

Companies in the U.S. dry eye disease diagnostic devices market are developing deep learning models that use an end-to-end black box, which help to improve patient outcomes. The algorithm in this model helps to highlight the patterns of tear film-corneal epithelium during the occlusion, which indicates its efficacy for differentiating AS-OCT images.

Corneal Topographers Help Assess Preoperative Conditions of Refractive Surgery Candidates

Apart from meibography and AS-OCT devices, eye doctors are opting for corneal topography, which is a computer assisted examination of the cornea. This examination is performed by projecting illuminated rings into the corneal surface and in turn, it comes back to be measured by the instrument.

It has been found that dry eye can affect corneal topography, which may increase HOAs (high-order aberrations) such as itching, burning sensations, and related visual symptoms. Hence, companies in the U.S. dry eye disease diagnostic devices market are increasing the availability of corneal topographers that are playing an instrumental role in preoperative conditions of refractive surgery candidates.

Ocular Surface Thermographers Emerging as Alternative to IR Thermographers

Ocular surface thermographers hold promising potentials to provide valuable insight into the status of the ocular surface. Advancements in the thermographic technology have increased the accuracy of ocular surface thermography measurements, and the technology is being increasingly applied to individuals with and without ocular surface diseases.

New ocular surface thermographers are emerging as an alternative to older infrared (IR) thermographers, since the former allows greater precision for measuring ocular surface thermography in real-time.

U.S. Dry Eye Disease Diagnostic Devices Market: Overview

  • According to Transparency Market Research’s latest research report on the dry eye disease diagnostic devices market in the U.S. for the historical period 2017–2019, considering 2020 as the base year, and the forecast period from 2021 to 2031, the dry eye disease diagnostic devices market in the U.S. was valued at US$ 58.3 Mn in 2020 and is projected to expand at a CAGR of 4.4% from 2021 to 2031
  • Rise in prevalence and incidence rates of dry eye disease in the U.S., technical advancements in dry eye disease diagnostic devices, adverse effects of rising pollution levels, and increase in use of electronics are anticipated to propel the market during the forecast period

Rise in Prevalence and Incidence Rates of Dry Eye Disease in U.S: Key Drivers

  • In the U.S., dry eye disease is considered a critical and significant public health issue. An article published in the American Journal of Ophthalmology stated that overall estimated prevalence of dry eye disease was 5.28% in the U.S. between 2003 and 2015.
  • It also indicated that the prevalence and incidence vary from 5% to 50%, and the prevalence is rising due to higher incidence of some risk factors and gradual increase, especially in the geriatric population. Hence, rise in prevalence of dry eye disease is expected to drive the market.
  • Surge in the geriatric population increases the risk of dry eye diseases. This, in turn, is likely to augment the dry eye disease diagnostic devices market in the U.S.
  • According to the American Journal of Ophthalmology, in the U.S., prevalence of dry eye disease increased with age from 0.20% for ages two to 17 years to 11.66% for individuals aged over 50 years. The geriatric population represented 16% of the population of the U.S. The number of elderly people in the country has increased by 14.4 million, or 36%, since 2009 compared to a rise of 3% for the under-65 population.
  • Therefore, surge in the geriatric population and rise in prevalence & incidence rates of dry eye disease in the U.S. are projected to drive the dry eye disease diagnostic devices market

Technical Advancements in Dry Eye Disease Diagnostic Devices: Major Driver

  • Dry eye is one of the most common problems faced by ophthalmologists. Its multiple causes have made it a challenge to diagnose. Companies focus on addressing this challenge and find a diagnostic method, thereby creating a more precise device for it.
  • Technological advancements enable ophthalmologists to provide fast, accurate, smooth diagnosis with enhanced efficiency. Hence, technological advancements is a significant driver of the dry eye disease diagnostic devices market in the U.S.
  • Innovative technology and unique usability of dry eye diagnostic devices create a new standard for dry eye analysis
  • These factors are anticipated to propel the dry eye disease diagnostic devices market in the U.S. during the forecast period

U.S. Dry Eye Disease Diagnostic Devices Market: Market Segmentation

  • In terms of device type, the dry eye disease diagnostic devices market in the U.S. has been classified into anterior segment OCT (AS-OCT), meibography device, corneal topographer, osmolarity testing device, ocular surface thermographer, interferometer, fluorophotometer, and others
  • Based on disease, the dry eye disease diagnostic devices market in the U.S. has been bifurcated into evaporative dry eye syndrome and aqueous dry eye syndrome
  • In terms of end-user, the dry eye disease diagnostic devices market in the U.S. has been divided into hospitals, diagnostic centers, ophthalmology centers/clinic, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The dry eye disease diagnostic devices market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Major Players

  • The dry eye disease diagnostic devices market report concludes with the company profiles section, which includes key information about major players in the dry eye disease diagnostic devices market in the U.S.
  • Leading players analyzed in the report include
    • Johnson & Johnson Services, Inc.
    • OCULUS Optikgeräte GmbH
    • Carl Zeiss Meditec AG
    • TearLab Corporation
    • Optovue, Inc.
    • AXIM Biotechnologies
    • Topcon Corporation
    • Quantel Medical
    • Essilor Instruments
    • I-MED Pharma, Inc.
    • Box Medical Solutions Inc.
    • NIDEK CO., LTD.
  • Each of these players has been profiled in the U.S. dry eye disease diagnostic devices market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

U.S. Dry Eye Disease Diagnostic Devices Market Snapshot

Attribute

Detail

Market Size Value in 2020 (Base Year)

US$ 58.3 Mn

Market Forecast Value in 2031

US$ 99.4 Mn

Growth Rate (CAGR)

4.4%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, pricing analysis, and parent industry overview.

Format

Electronic (PDF)

Market Segmentation

  • Device Type
    • Anterior Segment OCT (AS-OCT)
    • Meibography Device
    • Corneal Topographer
    • Osmolarity Testing Device
    • Ocular Surface Thermographer
    • Interferometer
    • Fluorophotometer
    • Others
  • Disease
    • Evaporative Dry Eye Syndrome
    • Aqueous Dry Eye Syndrome
  • End-user
    • Hospitals
    • Diagnostic Centers
    • Ophthalmology Centers/Clinic
    • Others

Country Covered

  • U.S.

Companies Covered

  • Johnson & Johnson Services, Inc.
  • OCULUS Optikgeräte GmbH
  • Carl Zeiss Meditec AG
  • TearLab Corporation
  • Optovue, Inc.
  • AXIM Biotechnologies
  • Topcon Corporation
  • Quantel Medical
  • Essilor Instruments
  • I-MED Pharma, Inc.
  • Box Medical Solutions Inc.
  • NIDEK CO., LTD.

Customization Scope

Available upon request

Pricing

Available upon request

U.S. Dry Eye Disease Diagnostic Devices Market – Segmentation

TMR’s study on the dry eye disease diagnostic devices market in the U.S. includes information divided into three segments: on device type, disease, and end-user.

Device Type
  • Anterior Segment OCT (AS-OCT)
  • Meibography Device
  • Corneal Topographer
  • Osmolarity Testing Device
  • Ocular Surface Thermographer
  • Interferometer
  • Fluorophotometer
  • Others
Disease
  • Evaporative Dry Eye Syndrome
  • Aqueous Dry Eye Syndrome
End-user
  • Hospitals
  • Diagnostic Centers
  • Ophthalmology Centers/Clinics
  • Others

Frequently Asked Questions

What is the total market worth of dry eye disease diagnostic devices market?

Dry eye disease diagnostic devices market in U.S. is expected to reach the value of US$ 99.4 Mn by the end of 2031

What is the anticipated CAGR of the dry eye disease diagnostic devices market in the forecast period?

Dry eye disease diagnostic devices market in U.S. to expand at a CAGR of 4.4% from 2021 to 2031

What are the key driving factors for the growth of the dry eye disease diagnostic devices market?

Dry eye disease diagnostic devices market in U.S. is driven by Rise in prevalence and incidence rates of dry eye disease

Which is the rising prominent segment in the dry eye disease diagnostic devices market?

The meibography device segment is expected to account for major share of the Dry Eye Disease Diagnostic Devices Market in the U.S.

Which is the rising prominent segment in the dry eye disease diagnostic devices market?

Key players in the dry eye disease diagnostic devices market in the U.S. include Johnson & Johnson Services, Inc., OCULUS Optikgeräte GmbH, Carl Zeiss Meditec AG, TearLab Corporation, Optovue, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: U.S. Dry Eye Disease Diagnostic Devices Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. U.S. Dry Eye Disease Diagnostic Devices Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Number of facilities for end-user types

        5.2. Technological Advancements

        5.3. Epidemiology of Dry Eye Disease in the U.S.

        5.4. Pricing Analysis

        5.5. Key Mergers & Acquisitions

        5.6. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    6. U.S. Dry Eye Disease Diagnostic Devices Market Analysis and Forecast, by Device Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Device Type, 2017–2031

            6.3.1. Anterior Segment OCT (AS-OCT)

            6.3.2. Ocular Surface Thermographer

            6.3.3. Corneal Topographer

            6.3.4. Osmolarity Testing Device

            6.3.5. Fluorophotometer

            6.3.6. Interferometer

            6.3.7. Meibography Device

            6.3.8. Others

        6.4. Market Attractiveness Analysis, by Device Type

    7. U.S. Dry Eye Disease Diagnostic Devices Market Analysis and Forecast, by Disease

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Disease, 2017–2031

            7.3.1. Evaporative Dry Eye Syndrome

            7.3.2. Aqueous Dry Eye Syndrome

        7.4. Market Attractiveness Analysis, by Disease

    8. U.S. Dry Eye Disease Diagnostic Devices Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Materials by End-user, 2017–2031

            8.3.1. Hospitals

            8.3.2. Diagnostic Centers

            8.3.3. Ophthalmology Centers/Clinic

            8.3.4. Others

        8.4. Market Attractiveness Analysis, by End-user

    9. Competition Landscape

        9.1. Company Profiles

            9.1.1. Johnson & Johnson Services, Inc.

                9.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.1.2. Product Portfolio

                9.1.1.3. SWOT Analysis

                9.1.1.4. Strategic Overview

            9.1.2. OCULUS Optikgeräte GmbH

                9.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.2.2. Product Portfolio

                9.1.2.3. SWOT Analysis

                9.1.2.4. Strategic Overview

            9.1.3. Carl Zeiss Meditec AG

                9.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.3.2. Product Portfolio

                9.1.3.3. SWOT Analysis

                9.1.3.4. Strategic Overview

            9.1.4. TearLab Corporation

                9.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.4.2. Product Portfolio

                9.1.4.3. SWOT Analysis

                9.1.4.4. Strategic Overview

            9.1.5. Optovue, Inc.

                9.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.5.2. Product Portfolio

                9.1.5.3. SWOT Analysis

                9.1.5.4. Strategic Overview

            9.1.6. AXIM Biotechnologies

                9.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.6.2. Product Portfolio

                9.1.6.3. SWOT Analysis

                9.1.6.4. Strategic Overview

            9.1.7. Topcon Corporation

                9.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.7.2. Product Portfolio

                9.1.7.3. SWOT Analysis

                9.1.7.4. Strategic Overview

            9.1.8. Quantel Medical

                9.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.8.2. Product Portfolio

                9.1.8.3. SWOT Analysis

                9.1.8.4. Strategic Overview

            9.1.9. Essilor Instruments

                9.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.9.2. Product Portfolio

                9.1.9.3. SWOT Analysis

                9.1.9.4. Strategic Overview

            9.1.10. I-MED Pharma inc.

                9.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.10.2. Product Portfolio

                9.1.10.3. SWOT Analysis

                9.1.10.4. Strategic Overview

            9.1.11. Box Medical Solutions Inc.

                9.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.11.2. Product Portfolio

                9.1.11.3. SWOT Analysis

                9.1.11.4. Strategic Overview

            9.1.12. NIDEK CO., LTD.

                9.1.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                9.1.12.2. Product Portfolio

                9.1.12.3. SWOT Analysis

                9.1.12.4. Strategic Overview

    List of Tables

    Table 01: Number of facilities for end-user types (2020)

    Table 02: Pricing Analysis

    Table 03: Key Development – Acquisitions & Mergers

    Table 04: U.S. Dry Eye Disease Diagnostic Devices Market Value (US$ Mn) Forecast, by Device Type, 2017–2031

    Table 05: U.S. Dry Eye Disease Diagnostic Devices Market Value (US$ Mn) Forecast, by Disease, 2017–2031

    Table 06: U.S. Dry Eye Disease Diagnostic Devices Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: U.S. Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: U.S. Dry Eye Disease Diagnostic Devices Market Value Share, by Device type, 2020

    Figure 03: U.S. Dry Eye Disease Diagnostic Devices Market Value Share, by Device, 2020

    Figure 04: U.S. Dry Eye Disease Diagnostic Devices Market Value Share, by End-user, 2020

    Figure 05: U.S. Dry Eye Disease Diagnostic Devices Market Value Share Analysis, by Device Type, 2020 and 2031

    Figure 06: U.S. Dry Eye Disease Diagnostic Devices Market Attractiveness Analysis, by Device Type, 2021–2031

    Figure 07: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Meibography Device, 2017–2031

    Figure 08: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Corneal Topographer, 2017–2031

    Figure 09: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Anterior Segment OCT (AS-OCT), 2017–2031

    Figure 10: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Osmolarity Testing Device, 2017–2031

    Figure 11: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Ocular Surface Thermographer, 2017–2031

    Figure 12: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Interferometer, 2017–2031

    Figure 13: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Fluorophotometer, 2017–2031

    Figure 14: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 15: U.S. Dry Eye Disease Diagnostic Devices Market Value Share Analysis, by Disease, 2020 and 2031

    Figure 16: U.S. Dry Eye Disease Diagnostic Devices Market Attractiveness Analysis, by Disease, 2021–2031

    Figure 17: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Evaporative Dry Eye Syndrome, 2017–2031

    Figure 18: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Aqueous Dry Eye Syndrome, 2017–2031

    Figure 19: U.S. Dry Eye Disease Diagnostic Devices Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 20: U.S. Dry Eye Disease Diagnostic Devices Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 21: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Hospitals, 2017–2031

    Figure 22: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031

    Figure 23: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Ophthalmology Centers/Clinics, 2017–2031

    Figure 24: U.S. Dry Eye Disease Diagnostic Devices Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 25: Johnson & Johnson - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 26: Johnson & Johnson - Medical Devices Segment - Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 27: Johnson & Johnson - Revenue Breakdown of Net Sales (%), by Business Segment, 2020

    Figure 28: Carl Zeiss Meditec AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 29: Carl Zeiss Meditec AG, Breakdown of Net Sales, by Geography/Region, 2020

    Figure 30: Carl Zeiss Meditec AG, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 31: Carl Zeiss Meditec AG, Breakdown of Net Sales, by Strategic Business Unit, 2020

    Figure 32: Topcon Corporation, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 33: Topcon Corporation, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 34: Topcon Corporation, Breakdown of Net Sales, by Geography/Region, 2020

    Figure 35: Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019

    Figure 36: Breakdown of Net Sales (%), by Segment, 2019

    Figure 37: Breakdown of Net Sales (%), by Domestic and International Sales, 2019

Copyright © Transparency Market Research, Inc. All Rights reserved